Scholarlink

Background <p>Antitumor drugs (such as chemotherapy, targeted therapy, immunotherapy, etc.) and local treatments like surgery and radiotherapy are widely used in cancer treatment, but they often carry the risk of liver injury, which seriously affects the prognosis and quality of life of patients. Therefore, liver protection is of crucial importance in cancer treatment.</p> Methods <p>Relevant experts organized by the Oncology Hepatology Committee of China Anti-Cancer Association Association formulated this guideline based on the latest research achievements and clinical practice experience at home and abroad, aiming to provide comprehensive and systematic guidance for clinicians on liver protection.</p> Results <p>This guideline elaborates on the importance of liver protection during cancer treatment, comprehensively introduces the pathophysiological mechanisms, diagnosis, treatment, and preventive measures of antitumor treatment-related liver injury.</p> Conclusion <p>This guideline is helpful for clinicians to formulate individualized treatment plans, improve the treatment outcome and quality of life of cancer patients, and provides an important reference for the clinical practice of liver protection in cancer treatment.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Liver protection of CACA technical guidelines for holistic integrative management of cancer

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年5月28日

查看全文
  • Ningning Zhang,
  • Lungen Lu,
  • Baoshan Cao,
  • Yanjing Gao,
  • Feng Han,
  • Liangping Li,
  • Qijiong Li,
  • Shuchen Li,
  • Xiaowu Li,
  • Jingfeng Liu,
  • Yefu Liu,
  • Yingqian Lv,
  • Yongzhan Nie,
  • Xizhong Shen,
  • Dongde Wu,
  • Qiang Wu,
  • Jun Xu,
  • Liping Yao,
  • Ning Zhang,
  • Yuzheng Zhuge,
  • Xiubao Ren,
  • De’an Tian,
  • Guohong Han,
  • Wei Lu,
  • Yan Bai,
  • Xiaobing Chen, Haining Fan, Xiaoping Guo,,
  • Yingbin Hu,
  • Weidong Jia,
  • Zuoyi Jiao,
  • Yongdong Jin,
  • Duo Li,
  • Runmei Li,
  • Wenxin Li,
  • Xiangcheng Li,
  • Yue Li,
  • Zhiwei Li,
  • Jing Liang,
  • Ting Lin,
  • Taotao Liu,
  • Liang Ma,
  • Jincheng Meng,
  • Tao Peng,
  • Chengyi Sun,
  • Zhiqiang Sun,
  • Hongwei Wang,
  • Lu Wang,
  • Shunxiang Wang,
  • Yusheng Wang,
  • Xiaoyong Wei,
  • Limin Xia,
  • Yijun Xia,
  • Qing Xie,
  • Tao Xin,
  • Jianhua Xu,
  • Liang Xu,
  • Qi Xu,
  • Dong Yan,
  • Changqing Yang,
  • Jinhui Yang,
  • Jianhua Yi,
  • Yongxiang Yi,
  • Lecheng Yu,
  • Songning Yu,
  • Liaoyun Zhang,
  • Yue Zhao,
  • Hong Zhu,
  • Ha Zhuang

摘要

Background

Antitumor drugs (such as chemotherapy, targeted therapy, immunotherapy, etc.) and local treatments like surgery and radiotherapy are widely used in cancer treatment, but they often carry the risk of liver injury, which seriously affects the prognosis and quality of life of patients. Therefore, liver protection is of crucial importance in cancer treatment.

Methods

Relevant experts organized by the Oncology Hepatology Committee of China Anti-Cancer Association Association formulated this guideline based on the latest research achievements and clinical practice experience at home and abroad, aiming to provide comprehensive and systematic guidance for clinicians on liver protection.

Results

This guideline elaborates on the importance of liver protection during cancer treatment, comprehensively introduces the pathophysiological mechanisms, diagnosis, treatment, and preventive measures of antitumor treatment-related liver injury.

Conclusion

This guideline is helpful for clinicians to formulate individualized treatment plans, improve the treatment outcome and quality of life of cancer patients, and provides an important reference for the clinical practice of liver protection in cancer treatment.